JP2018509451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509451A5 JP2018509451A5 JP2017550129A JP2017550129A JP2018509451A5 JP 2018509451 A5 JP2018509451 A5 JP 2018509451A5 JP 2017550129 A JP2017550129 A JP 2017550129A JP 2017550129 A JP2017550129 A JP 2017550129A JP 2018509451 A5 JP2018509451 A5 JP 2018509451A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- atom
- carbon
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052799 carbon Inorganic materials 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000005842 heteroatom Chemical group 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001721 carbon Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- 125000004434 sulfur atom Chemical group 0.000 claims 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 7
- 229910052794 bromium Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- 239000011737 fluorine Substances 0.000 claims 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229940116269 uric acid Drugs 0.000 claims 3
- -1 2,6-dichlorophenyl Chemical group 0.000 claims 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims 2
- 108010093894 Xanthine oxidase Proteins 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical group [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical group [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229910001424 calcium ion Chemical group 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960005101 febuxostat Drugs 0.000 claims 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 150000002926 oxygen Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 1
- 0 CCC=C(*[*@@](*)C(C(*)=CC=C)=CC)[U]*(C(*)(**)C(ON)=O)=C Chemical compound CCC=C(*[*@@](*)C(C(*)=CC=C)=CC)[U]*(C(*)(**)C(ON)=O)=C 0.000 description 12
- WBIBFBMAQJQKNP-UHFFFAOYSA-N CC(C)c(cc1)cc(Cl)c1C#N Chemical compound CC(C)c(cc1)cc(Cl)c1C#N WBIBFBMAQJQKNP-UHFFFAOYSA-N 0.000 description 1
- HEXWBLFHVBQWAG-UHFFFAOYSA-N N=Cc1c2OCCOc2ccc1 Chemical compound N=Cc1c2OCCOc2ccc1 HEXWBLFHVBQWAG-UHFFFAOYSA-N 0.000 description 1
- LUSIZUFVMKYWGX-UHFFFAOYSA-N Nc(c1c2cccc1)ccc2C#N Chemical compound Nc(c1c2cccc1)ccc2C#N LUSIZUFVMKYWGX-UHFFFAOYSA-N 0.000 description 1
- DMLRSJNZORFCBD-UHFFFAOYSA-N Nc1c2OCCOc2ccc1 Chemical compound Nc1c2OCCOc2ccc1 DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510131828 | 2015-03-24 | ||
| CN201510131828.5 | 2015-03-24 | ||
| PCT/CN2016/073043 WO2016150255A1 (zh) | 2015-03-24 | 2016-02-01 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509451A JP2018509451A (ja) | 2018-04-05 |
| JP2018509451A5 true JP2018509451A5 (enExample) | 2018-07-05 |
| JP6449482B2 JP6449482B2 (ja) | 2019-01-09 |
Family
ID=56977003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550129A Active JP6449482B2 (ja) | 2015-03-24 | 2016-02-01 | 縮合環誘導体、その製造方法、中間体、薬学的組成物及び応用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10100015B2 (enExample) |
| EP (1) | EP3275867B1 (enExample) |
| JP (1) | JP6449482B2 (enExample) |
| KR (1) | KR102087918B1 (enExample) |
| CN (3) | CN108299425B (enExample) |
| AU (1) | AU2016236669B2 (enExample) |
| CA (1) | CA2980484C (enExample) |
| IL (1) | IL254098B (enExample) |
| MX (1) | MX383376B (enExample) |
| NZ (1) | NZ735044A (enExample) |
| RU (1) | RU2683566C1 (enExample) |
| SG (1) | SG11201706869XA (enExample) |
| TW (2) | TWI675026B (enExample) |
| WO (1) | WO2016150255A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108299425B (zh) | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| US10494378B2 (en) * | 2015-07-21 | 2019-12-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| NZ749427A (en) * | 2016-05-23 | 2019-11-29 | Cstone Pharmaceutical Suzhou Co Ltd | Thiophene, manufacturing method thereof, and pharmaceutical application of same |
| CN106146533B (zh) * | 2016-07-14 | 2018-04-03 | 华润赛科药业有限责任公司 | 含硫杂环羧酸类衍生物、其制备方法和应用 |
| CN106083847B (zh) * | 2016-08-03 | 2018-10-30 | 山东大学 | 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用 |
| CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108033909A (zh) * | 2017-12-20 | 2018-05-15 | 北京六合宁远科技有限公司 | 一种6-甲基-4-溴-异喹啉的制备方法 |
| CN109608432B (zh) * | 2018-12-17 | 2022-10-11 | 江苏艾立康医药科技有限公司 | 作为urat1抑制剂的噻吩类衍生物 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN111303161B (zh) * | 2020-04-14 | 2021-01-05 | 遵义医科大学珠海校区 | 嘧啶并氮杂环类化合物及其用途 |
| CN111763218B (zh) * | 2020-07-14 | 2021-05-28 | 山东大学 | 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用 |
| CA3246483A1 (en) * | 2022-01-04 | 2025-06-13 | Shanghai Yingli Pharmaceutical Co., Ltd | Crystal form of a fused ring derivative, a prepartion method therefor and use thereof |
| CN116465985B (zh) * | 2023-03-03 | 2024-12-10 | 连云港杰瑞药业有限公司 | 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法 |
| WO2024209363A1 (en) | 2023-04-06 | 2024-10-10 | Pfizer Inc. | Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators |
| CN118955327A (zh) * | 2024-06-26 | 2024-11-15 | 安徽大学 | 一种4-溴-1-萘甲腈的合成方法 |
| CN118878551B (zh) * | 2024-07-08 | 2026-04-28 | 安徽大学 | 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558655A (en) | 1969-06-25 | 1971-01-26 | Parke Davis & Co | Benzo(b)thiopheneacetic acid compounds |
| US4224330A (en) | 1979-09-13 | 1980-09-23 | Zoecon Corporation | Esters and thiolesters of benzothienyl acids |
| AUPO282896A0 (en) | 1996-10-07 | 1996-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Novel compounds |
| ES2270867T3 (es) | 1999-09-23 | 2007-04-16 | Astrazeneca Ab | Compuestos de quinazolina terapeuticos. |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| WO2005051940A2 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Vitamin d receptor modulators |
| ATE418567T1 (de) * | 2003-12-22 | 2009-01-15 | Basell Polyolefine Gmbh | Metallocenverbindungen |
| SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
| GB0426313D0 (en) * | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| US8916550B2 (en) * | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| AU2007210076A1 (en) * | 2006-01-30 | 2007-08-09 | Irm Llc | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as PPAR modulators |
| MX2008011723A (es) | 2006-03-16 | 2008-09-26 | Astellas Pharma Inc | Derivado de triazol o su sal. |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| JP2011520809A (ja) | 2008-05-05 | 2011-07-21 | アムジエン・インコーポレーテツド | γセクレターゼモジュレーターとしての尿素化合物 |
| EP2427430B1 (en) * | 2009-05-04 | 2014-09-10 | The Royal Institution for the Advancement of Learning/McGill University | 5-oxo-ete receptor antagonist compounds |
| TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
| WO2011150156A2 (en) * | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| TWI499412B (zh) * | 2010-06-16 | 2015-09-11 | 亞德生化公司 | 苯基硫乙酸酯組合物及其使用方法 |
| EP2632922B1 (de) | 2010-10-27 | 2019-02-27 | Bayer CropScience Aktiengesellschaft | Heteroarylpiperidin und -piperazinderivate als fungizide |
| JP5990106B2 (ja) * | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| US8957203B2 (en) * | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| WO2014017643A1 (ja) | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
| RU2015120217A (ru) * | 2012-11-20 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Замещенные 1,6-нафтиридины |
| JP6113354B2 (ja) * | 2013-05-03 | 2017-04-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経新生刺激イソキノリン誘導体 |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| MX385777B (es) * | 2014-12-24 | 2025-03-04 | Lg Chemical Ltd | Derivado de biarilo como agonista de gpr120. |
| CN108299425B (zh) | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
-
2016
- 2016-02-01 CN CN201810188235.6A patent/CN108299425B/zh active Active
- 2016-02-01 CN CN201610071297.XA patent/CN106008340B/zh active Active
- 2016-02-01 CN CN201810188236.0A patent/CN108516958B/zh active Active
- 2016-02-01 KR KR1020177029920A patent/KR102087918B1/ko active Active
- 2016-02-01 SG SG11201706869XA patent/SG11201706869XA/en unknown
- 2016-02-01 NZ NZ735044A patent/NZ735044A/en unknown
- 2016-02-01 WO PCT/CN2016/073043 patent/WO2016150255A1/zh not_active Ceased
- 2016-02-01 JP JP2017550129A patent/JP6449482B2/ja active Active
- 2016-02-01 EP EP16767632.9A patent/EP3275867B1/en active Active
- 2016-02-01 US US15/559,181 patent/US10100015B2/en active Active
- 2016-02-01 RU RU2017134044A patent/RU2683566C1/ru active
- 2016-02-01 CA CA2980484A patent/CA2980484C/en active Active
- 2016-02-01 AU AU2016236669A patent/AU2016236669B2/en active Active
- 2016-02-01 MX MX2017012009A patent/MX383376B/es unknown
- 2016-03-24 TW TW105109178A patent/TWI675026B/zh active
- 2016-03-24 TW TW106139600A patent/TWI666201B/zh active
-
2017
- 2017-08-22 IL IL254098A patent/IL254098B/en active IP Right Grant
-
2018
- 2018-05-22 US US15/985,848 patent/US10100016B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11236058B2 (en) | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia | |
| AR053415A1 (es) | Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion | |
| JP2021527126A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| RU2012121577A (ru) | Замещенные 3-фенилпропионовые кислоты и их применение | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| BR0316586A (pt) | Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
| JP2016518437A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| RU2012112471A (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета | |
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2017538689A5 (enExample) | ||
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| RU2017121460A (ru) | Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение | |
| JP2012526769A5 (enExample) | ||
| JP2017502092A5 (enExample) | ||
| WO2019244000A1 (en) | Phenyl and pyridinyl substituted imidazoles as modulators of roryt | |
| JOP20240120A1 (ar) | مشتقات 4-فينيل-2-(1h-3،2،1-تريازول-4-يل) بيبيريدين-4-أول كمثبطات لـ apol1 وطرق استخدامها | |
| RU2012135698A (ru) | Способ и композиция | |
| JP2018502141A5 (enExample) | ||
| AU2018326721A1 (en) | Compounds and compositions for IRE1 inhibition | |
| RU2017117179A (ru) | Производные пиридооксазинона в качестве ингибиторов tnap | |
| RU2008119994A (ru) | Ингибиторы калиевых каналов | |
| JP2005533052A5 (enExample) |